...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes.
【24h】

CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes.

机译:人脑动脉中的CGRP和肾上腺髓质素受体群:不同动脉大小的体外药理和分子研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The aim of the present study was to determine functional and molecular characteristics of receptors for calcitonin gene-related peptide (CGRP) and adrenomedullin in three different diameter groups of lenticulostriate arteries. Furthermore, the presence of perivascular neuronal sources of CGRP was evaluated in these arteries. In the functional studies, in vitro pharmacological experiments demonstrated that both CGRP and adrenomedullin induce alpha-CGRP-(8-37) sensitive vasodilation in artery segments of various diameters. The maximal amounts of vasodilation induced by CGRP and adrenomedullin were not different, whereas the potency of CGRP exceeded that of adrenomedullin by 2 orders of magnitude. Significant negative correlations between artery diameters and maximal responses were demonstrated for CGRP and adrenomedullin. In addition, the potency of both peptides tended to increase in decreasing artery diameter. In the molecular experiments, levels of mRNAs encoding CGRP receptors and receptor subunits were compared using reverse transcriptase polymerase chain reactions (RT-PCR). The larger the artery, the more mRNA encoding receptor activity-modifying proteins 1 and 2 (RAMP1 and RAMP2) was detected relative to the amount of mRNA encoding the calcitonin receptor-like receptor. By immunohistochemistry, perivascular CGRP containing nerve fibres were demonstrated in all the investigated artery sizes. In conclusion, both CGRP and adrenomedullin induced vasodilation via CGRP receptors in human lenticulostriate artery of various diameter. The artery responsiveness to the CGRP receptor agonists increased with smaller artery diameter, whereas the receptor-phenotype determining mRNA ratios tended to decrease. No evidence for CGRP and adrenomedullin receptor heterogeneity was present in lenticulostriate arteries of different diameters.
机译:本研究的目的是确定降钙素基因相关肽(CGRP)和肾上腺髓质素在三个不同直径的细齿动脉组中的受体的功能和分子特征。此外,在这些动脉中评估了CGRP的血管周围神经元来源。在功能研究中,体外药理实验表明,CGRP和肾上腺髓质素均可诱导不同直径的动脉节段中的α-CGRP-(8-37)敏感血管舒张。 CGRP和肾上腺髓质素诱导的最大血管舒张量没有差异,而CGRP的效力超过肾上腺髓质素的2个数量级。 CGRP和肾上腺髓质素在动脉直径和最大反应之间呈显着负相关。另外,两种肽的效力在减小的动脉直径中趋于增加。在分子实验中,使用逆转录聚合酶链反应(RT-PCR)比较了编码CGRP受体和受体亚基的mRNA的水平。相对于编码降钙素受体样受体的mRNA量,动脉越大,检测到的编码受体活性修饰蛋白1和2的mRNA越多(RAMP1和RAMP2)。通过免疫组织化学,在所有研究的动脉大小中均证实了包含神经纤维的血管周围CGRP。总之,CGRP和肾上腺髓质素都通过CGRP受体诱导了各种直径的人细齿动脉的血管舒张。动脉对CGRP受体激动剂的反应性随动脉直径的减小而增加,而受体表型决定的mRNA比率则趋于下降。在不同直径的细网状动脉中未发现CGRP和肾上腺髓质素受体异质性的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号